Ligand id: 6780

Name: rituximab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rituximab

Immunopharmacology Comments
Rituximab is the first biological agent to show positive effects on biological and clinical disease parameters in Sjögren's syndrome [1,7].
Immunopharmacology Disease
Disease X-Refs Comment References
Chronic lymphocytic leukemia Disease Ontology: DOID:1040
OMIM: 151400
Orphanet: ORPHA67038
An anti-CD20 therapy approved for CLL and non-Hodgkins lymphoma.
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
An anti-CD20 therapy approved for RA.
Pemphigus Disease Ontology: DOID:9182
Rituximab is the first biologic therapy approved for pemphigus vulgaris (PV), and represents the first major PV therapeutic advance in more than 60 years.